Trends in Drug Development Costs,Times,and Risks

Hansen RW . The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: Issues in pharmaceutical economics. Chien RI ed. Lexington, MA: Lexington Books DC Heath; 1979.

DiMasi JA Hansen RW Grabowski HG Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10(2):107–142.

U.S. Congress Office of Technology Assessment . Pharmaceutical R&D: costs, risks, and rewards. (OTA-H-522) Washington DC: GPO; 1993.

Faust RE Harris MR Lee KI . Factors which can harm the patient: economic restraints on research and development in the pharmaceutical industry. In: Regulation and restraint in contemporary medicine in the U.K. and U.S.A. L'Etang H ed. London: Royal Society of Medicine and MacMillan Press Ltd; 1983.

Halliday RG Walker SR Lumley CE . R&D philosophy and management in the world's leading pharmaceutical companies. J Pharm Med. 1992;2:139–154.

James B. The future of the multinational pharmaceutical industry to 1990 London: Associated Business Programmes, Ltd.; 1977.

Wardell WM . The history of drug discovery, development, and regulation. In: Issues in pharmaceutical economics. Chien RI ed. Lexington, MA: Lexington Books DC Heath; 1979.

Wardell WM DiRaddo J Trimble AG . Development of new drugs originated and acquired by United States-owned pharmaceutical firms 1963-76. Clin Pharmacol Ther. 1980;28:270–277.

DiMasi JA Hansen RW Grabowski HG Lasagna L. Research and development costs for new drugs by therapeutic category. PharmacoEcon. 1995;7(2):152–169.

Wardell WM Hassar M Anavekar SN Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther. 1978;24(2):133–145.

Wardell WM May MS Trimble AG . New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-79. Clin Pharmacol Ther. 1982;32(4):407–417.

May MS Wardell WM Lasagna L. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979. Clin Pharmacol Ther. 1983;33(6):691–700.

Mattison N Trimble AG Lasagna L. New drug development in the United States, 1963 through 1984. Clin Pharmacol Ther. 1988;43(3):290–301.

DiMasi JA Bryant NR Lasagna L. New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther. 1991;50(5 Pt 1): 471–486.

DiMasi JA Seibring MA Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther. 1994;55(6):609–622.